Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guri-si
Clinical trial register · South Korea

Clinical Trials in Guri-si, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company8 Novartis Pharmaceuticals4 AbbVie4 AstraZeneca4 EverEx Inc.2
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Guri-si

38 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Eli Lilly and Company
Phase 3
2,001
Ansan-si, Anyang-si, Busan, Guri-si, Gwangju, Junggu, Seogu, Seongnam
2026-08-26
Recruiting
AstraZeneca
Phase 3
7,000
Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Guri-si, Junggu, Seoul
2026-08-21
Recruiting
AstraZeneca
Phase 3
1,200
Busan, Changwon-si, Daegu, Daejeon, Guri-si, Incheon, Seoul
2026-07-06
Recruiting
AstraZeneca
Phase 3
2,000
Goyang-si, Guri-si, Gwangju, Gyeonggi-do, Seoul, Yangsan
2026-07-06
Active, closed
EverEx Inc.
Not applicable
156
Guri-si, Gwangmyeong, Uijeongbu-si, Seoul
2026-03-19
Recruiting
Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
NCT07687706Ischemic Stroke, Ischemic Stroke, Acute, Transient Ischemic Attack (TIA), Cerebrovascular Disease
DrugTegoprazan
Hanyang University Guri Hospital
Phase 3
1,524
Busan, Daegu, Chuncheon, Anyang-si, Iksan, Jeonju, Cheongju-si, Guri-si
2026-01-26
Not yet open
Inha University Hospital
Phase 4
1,898
Incheon, Ansan, Bucheon-si, Busan, Cheonan, Goyang, Goyang-si, Guri-si
2026-01-01
Recruiting
ROKIT Healthcare
Phase 4
104
Daegu, Bucheon-si, Guri-si, Gwangmyeong, Seongnam-si, Goyang, Incheon, Jeonju
2025-12-29
Recruiting
Eli Lilly and Company
Phase 3
1,035
Ansan-si, Guri-si, Gwangju, Seongnam, Seoul
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
7,140
Busan, Daegu, Guri-si, Gwangju, Namdong-gu, Seongnam, Seoul, Ulsan
2025-12-01
Recruiting
Eli Lilly and Company
Phase 3
1,100
Anyang-si, Busan, Cheongju-si, Guri-si, Incheon, Junggu, Namdong-gu, Seogu
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Ansan-si, Bucheon-si, Busan, Daegu, Dongjak-gu, Guri-si, Incheon, Jinju
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Busan, Cheongju-si, Guri-si, Junggu, Namdong-gu, Seogu, Seongnam, Seoul
2025-10-15
Recruiting
AstraZeneca
Observational
130
Busan, Daejeon, Goyang-si, Guri-si, Incheon, Seongnam-si, Seoul, Suwon
2025-10-15
Recruiting
NeuroBiogen Co., Ltd
Phase 2
114
Gwangju, Guri-si, Suwon, Incheon, Seoul
2025-08-06
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
220
Cheonan, Guri-si, Seongnam-si, Seoul
2025-07-28
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Daegu, Goyang, Guri-si, Seoul
2025-06-19
Recruiting
Boryung Pharmaceutical Co., Ltd
Phase 2
120
Daegu, Guri-si
2025-05-30
Recruiting
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
NCT06962098Diabetic Kidney Disease (DKD)
Aptabio Therapeutics, Inc.
Phase 2
186
Ansan-si, Busan, Cheonan, Daegu, Goyang-si, Guri-si, Gwangmyeong, Incheon
2025-05-26
Recruiting
Hoffmann-La Roche
Phase 3
600
Busan, Daegu, Daejeon, Gangwon-do, Guri-si, Seoul
2025-03-17
Active, closed
Boehringer Ingelheim
Phase 3
11,000
Ansan-si, Busan, Cheonan-si, Cheongju-si, Daegu, Deagu, Goyang-si, Guri-si
2024-08-30
Recruiting
CSL Behring
Phase 2/3
3,110
Ilsan-gu, Anyang-si, Daegu, Gangnam-gu, Goyang-si, Guri-si, Gwangju, Seoul
2024-04-27
Active, closed
EverEx Inc.
Not applicable
216
Goyang-si, Guri-si, Gyeonggi-do, Seongnam-si, Junggu, Dongjak, Gangdong, Seocho
2024-04-26
Recruiting
CMG Pharmaceutical Co. Ltd
Phase 3
240
Anyang, Buchon, Busan, Cheonan, Daegu, Daejeon, Goyang-si, Guri-si
2024-04-19
Active, closed
Gilead Sciences
Phase 2
228
Busan, Daegu, Daejeon, Guri-si, Jongno-Gu, Nam-Gu, Seongdong-gu, Seoul
2024-03-27
Active, closed
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
NCT05995600Antiphospholipid Syndrome, Ischemic Stroke, Transient Ischemic Attack, Cerebrovascular Disease
DrugWarfarin
Seoul National University Hospital
Phase 4
200
Anyang, Busan, Cheongju-si, Chuncheon, Daegu, Daejeon, Guri-si, Gwangju
2024-02-20
Recruiting
Seoul National University Hospital
Phase 2
29
Guri-si, Seoul
2023-07-07
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Dongan-Gu, Anyang-Si, Guri-si, Uijeongbu-si, Jongno-gu, Seodaemun-gu, Seongbuk-Gu, Cheonan, Daejeon
2023-07-06
Active, closed
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
NCT05732402Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
DrugPovetacicept
Alpine Immune Sciences, Inc.
Phase 1/2
72
Cheonan, Anyang-si, Goyang-si, Guri-si, Seoul, Suwon
2023-03-15
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Seongnam-si, Gwangju, Seoul, Chuncheon, Incheon, Cheonan, Daegu, Guri-si
2022-12-23
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Busan, Guri-si, Gwangju, Incheon, Junggu, Namdong-gu, Seongnam, Seongnam-si
2022-10-10
Active, closed
Novartis Pharmaceuticals
Observational
670
Daegu, Kangwon Do, Wŏnju, Goyang-si, Guri-si, Jinju, Jeonju, Iksan Si
2022-05-09
Recruiting
Regulatory Post-Marketing Surveillance Study for Brolucizumab
NCT04985487Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals
Observational
3,000
Daegu, Goyang-si, Guri-si, Suwon, Iksan Si, Daejeon, Busan, Gwangju
2021-08-18
Active, closed
Eli Lilly and Company
Phase 3
996
Wŏnju, Ansan-si, Guri-si, Suwon, Gyeongsan-si, Busan, Haeundae-gu, Dongjak-gu
2020-06-22
Active, closed
AbbVie
Phase 3
1,242
Busan, Daejeon, Guri-si, Seongnam, Suwon, Seoul, Daegu
2018-08-28
Active, closed
AbbVie
Phase 3
1,336
Busan, Daegu, Daejeon, Guri-si, Seongnam-si, Suwon, Seoul
2018-04-09
Active, closed
AbbVie
Phase 3
747
Busan, Daegu, Guri-si, Seongnam-si, Dongjak-gu, Seoul
2018-03-21
Active, closed
AbbVie
Phase 3
950
Busan, Guri-si, Seongnam, Suwon, Seoul, Daegu
2017-01-31
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/guri-si

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies with a site in Guri-si.

How many clinical trials are recruiting in Guri-si?

22 of the 38 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guri-si), 38 studies
PhaseStudiesRecruitingShare
Phase 3221357.9%
Phase 26515.8%
Observational327.9%
Phase 4317.9%
Not applicable205.3%
Phase 1/2102.6%
Phase 2/3112.6%

Most active sponsors

Lead sponsors with the most studies (Guri-si)
Lead sponsorStudiesRecruiting
Eli Lilly and Company86
AbbVie40
AstraZeneca44
Novartis Pharmaceuticals42
EverEx Inc.20
Seoul National University Hospital21
Alpine Immune Sciences, Inc.10
Aptabio Therapeutics, Inc.11
AriBio Co., Ltd.10
Boehringer Ingelheim10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.